SCHEMBL485505

SCHEMBL485505

COc1ccc(C#Cc2c(C(=O)NC3CCCC3)ccc3ccccc23)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
MAPT P10636 2/20 0.52
DRD4 P21917 2/20 0.50
KLK7 P49862 1/20 0.48
ALDH1A1 P00352 4/20 0.47
KDM4E B2RXH2 3/20 0.47
HPGD P15428 3/20 0.47
HSD17B10 Q99714 1/20 0.47
NPC1 O15118 3/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
CNR1 P21554 1/20 0.44
CNR2 P34972 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
AKR1B10 O60218 1/20 0.43
AKR1B1 P15121 1/20 0.43
HPGDS O60760 1/20 0.43
NR1I2 O75469 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicarbonate SCHEMBL486058 0.98 MAPT (0.52) RAB9AL3MBTL1MAPTDRD4KLK7
SCHEMBL485779 0.86 DRD4 (0.48) RAB9AL3MBTL1MAPTDRD4ALDH1A1
Bicarbonate SCHEMBL486033 0.84 GAA (0.48) RAB9AMAPTDRD4ALDH1A1KDM4E
SCHEMBL485313 0.79 CXCR2 (0.52) RAB9AMAPTKDM4ENPC1MEN1
SCHEMBL485335 0.78 CXCR2 (0.58) RAB9AL3MBTL1MAPTKDM4ENPC1
SCHEMBL485444 0.76 PYGL (0.42) RAB9AMAPTALDH1A1KDM4ENPC1
SCHEMBL485442 0.76 PYGL (0.42) RAB9AMAPTALDH1A1KDM4ENPC1
SCHEMBL28797613 0.72 APP (0.51) L3MBTL1MAPTALDH1A1KDM4EHSD17B10
SCHEMBL29481000 0.71 NPC1 (0.58) RAB9AL3MBTL1MAPTALDH1A1KDM4E
SCHEMBL67733 0.71 NPC1 (0.58) RAB9AL3MBTL1MAPTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836158-B1 FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION SANOFI AVENTIS DEUTSCHLAND (DE) 2012-02-01 EP claimed